IL271211B2 - Acetyl-leucine for use in treatment of migraine - Google Patents

Acetyl-leucine for use in treatment of migraine

Info

Publication number
IL271211B2
IL271211B2 IL271211A IL27121119A IL271211B2 IL 271211 B2 IL271211 B2 IL 271211B2 IL 271211 A IL271211 A IL 271211A IL 27121119 A IL27121119 A IL 27121119A IL 271211 B2 IL271211 B2 IL 271211B2
Authority
IL
Israel
Prior art keywords
leucine
acetyl
pharmaceutically acceptable
acceptable salt
use according
Prior art date
Application number
IL271211A
Other languages
English (en)
Hebrew (he)
Other versions
IL271211B1 (en
IL271211A (en
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59358204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL271211(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of IL271211A publication Critical patent/IL271211A/en
Publication of IL271211B1 publication Critical patent/IL271211B1/en
Publication of IL271211B2 publication Critical patent/IL271211B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL271211A 2017-06-14 2018-06-25 Acetyl-leucine for use in treatment of migraine IL271211B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine

Publications (3)

Publication Number Publication Date
IL271211A IL271211A (en) 2020-01-30
IL271211B1 IL271211B1 (en) 2023-09-01
IL271211B2 true IL271211B2 (en) 2024-01-01

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271211A IL271211B2 (en) 2017-06-14 2018-06-25 Acetyl-leucine for use in treatment of migraine

Country Status (25)

Country Link
US (1) US11471434B2 (enExample)
EP (1) EP3638370B1 (enExample)
JP (1) JP7130739B2 (enExample)
KR (1) KR102594130B1 (enExample)
CN (1) CN111093772B (enExample)
AU (1) AU2018284330B2 (enExample)
CY (1) CY1123860T1 (enExample)
DK (1) DK3638370T3 (enExample)
ES (1) ES2847169T3 (enExample)
GB (1) GB201709459D0 (enExample)
HR (1) HRP20210108T1 (enExample)
HU (1) HUE053089T2 (enExample)
IL (1) IL271211B2 (enExample)
LT (1) LT3638370T (enExample)
MA (1) MA49396B1 (enExample)
MD (1) MD3638370T2 (enExample)
MX (1) MX387909B (enExample)
PL (1) PL3638370T3 (enExample)
PT (1) PT3638370T (enExample)
RS (1) RS61481B1 (enExample)
SG (1) SG11201912146RA (enExample)
SI (1) SI3638370T1 (enExample)
SM (1) SMT202100037T1 (enExample)
WO (1) WO2018229738A1 (enExample)
ZA (1) ZA201908087B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019221886B2 (en) * 2018-02-15 2024-08-08 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
JP7471298B2 (ja) 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288447A1 (en) * 1987-04-22 1988-10-26 Anders Hamberger Composition for the treatment of migraine, by influencing thenerve cells.
WO2012064892A1 (en) * 2010-11-09 2012-05-18 Mannkind Corporation Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
EP1641775B1 (en) * 2003-07-03 2009-02-18 Euro-Celtique S.A. 2-pyridine alkyne derivatives useful for treating pain
CN1856484B (zh) * 2003-07-24 2010-09-22 欧洲凯尔蒂克公司 用于治疗或预防疼痛的杂芳基-四氢吡啶基化合物
JP4634385B2 (ja) * 2003-09-22 2011-02-16 ユーロ−セルティーク エス．エイ． 疼痛の治療に有用なフェニル−カルボキサミド化合物
DE602004017481D1 (de) * 2003-09-22 2008-12-11 Euro Celtique Sa Zur behandlung von schmerzen geeignete therapeutische mittel
DE602004019576D1 (de) * 2003-12-30 2009-04-02 Euro Celtique Sa Zur behandlung von schmerzen geeignete piperazine
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
JP5876423B2 (ja) * 2010-06-22 2016-03-02 塩野義製薬株式会社 Ｔｒｐｖ１阻害活性を有する化合物とその使用
EP3103469B1 (en) 2010-06-25 2020-12-09 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
WO2013021276A1 (en) * 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
KR102791288B1 (ko) 2016-04-19 2025-04-03 인트라바이오 리미티드 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
MA43876B1 (fr) 2016-08-11 2019-04-30 Intrabio Ltd Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
AU2017308865B2 (en) 2016-08-11 2023-04-13 Intrabio Limited Therapeutic agents for neurodegenerative diseases
LT3600276T (lt) 2017-03-28 2023-08-10 Intrabio Ltd Betahistinas arba farmaciniu požiūriu priimtina jo druska ir monoaminooksidazės inhibitorius, skirti panaudoti subjekto gydymui arba profilaktikai vieno arba daugiau vestibulinio galvos svaigimo simptomų
RU2763425C2 (ru) 2017-10-18 2021-12-29 Интрабио Лимитед Терапевтические агенты для нейродегенеративных заболеваний
WO2019079536A1 (en) 2017-10-18 2019-04-25 Intrabio Ltd THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS
AU2019221886B2 (en) 2018-02-15 2024-08-08 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
JP7471298B2 (ja) 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体
SI3934637T1 (sl) 2019-03-02 2024-10-30 Intrabio Ltd Summit House (N-)acetil-L-levcin za uporabo pri zdravljenju travmatske poškodbe možganov
PL3989962T3 (pl) 2019-06-28 2025-11-17 Intrabio Ltd Terapia skojarzona acetyloleucyną i miglustatem w leczeniu lizosomalnej choroby spichrzeniowej
US20230051742A1 (en) 2020-01-13 2023-02-16 Intrabio Ltd. Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288447A1 (en) * 1987-04-22 1988-10-26 Anders Hamberger Composition for the treatment of migraine, by influencing thenerve cells.
WO2012064892A1 (en) * 2010-11-09 2012-05-18 Mannkind Corporation Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines

Also Published As

Publication number Publication date
PL3638370T3 (pl) 2021-05-17
KR20210013518A (ko) 2021-02-04
SMT202100037T1 (it) 2021-03-15
ES2847169T3 (es) 2021-08-02
DK3638370T3 (da) 2021-01-25
US20200253905A1 (en) 2020-08-13
CN111093772A (zh) 2020-05-01
CN111093772B (zh) 2023-11-03
ZA201908087B (en) 2024-11-27
SI3638370T1 (sl) 2021-04-30
CY1123860T1 (el) 2022-05-27
WO2018229738A1 (en) 2018-12-20
AU2018284330B2 (en) 2024-03-14
IL271211B1 (en) 2023-09-01
MA49396B1 (fr) 2021-03-31
RU2020100475A (ru) 2021-07-14
KR102594130B1 (ko) 2023-10-24
JP7130739B2 (ja) 2022-09-05
CA3067321A1 (en) 2018-12-20
MD3638370T2 (ro) 2021-04-30
HRP20210108T1 (hr) 2021-03-19
EP3638370B1 (en) 2020-11-11
EP3638370A1 (en) 2020-04-22
JP2020526575A (ja) 2020-08-31
US11471434B2 (en) 2022-10-18
BR112019026660A2 (pt) 2020-07-14
MX387909B (es) 2025-03-19
MA49396A (fr) 2020-04-22
RU2020100475A3 (enExample) 2021-10-22
MX2019014784A (es) 2021-11-16
AU2018284330A1 (en) 2020-01-02
HUE053089T2 (hu) 2021-06-28
SG11201912146RA (en) 2020-01-30
PT3638370T (pt) 2021-01-26
RS61481B1 (sr) 2021-03-31
LT3638370T (lt) 2021-03-25
GB201709459D0 (en) 2017-07-26
IL271211A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
US10058529B2 (en) Nutraceutical composition for PDE4 inhibition, enhanced dopamine metabolism and long term potentiation
Ng et al. Potassium channel openers and prostacyclin play a crucial role in mediating the vasorelaxant activity of Gynura procumbens
US9060999B2 (en) Ellagitannins rich extracts composition
JP2020522487A (ja) ストレス障害のホルモンカスケードを調節する組成物および方法
WO2014175773A1 (ru) Средство для нормализации сна и биологических ритмов
US20060233892A1 (en) Topiramate compositions for treatment of headache
IL271211B2 (en) Acetyl-leucine for use in treatment of migraine
WO2004073645A3 (en) Inhibition of olfatory neurosensory function of treat eating disorders and obesity
AU2021322255A8 (en) Use of dexpramipexole for the treatment of moderate to severe asthma
Woolf et al. Nondrug interventions for treatment of hypertension
Rivera-García et al. The resurgence of hallucinogen drugs in clinical research
KR20240004452A (ko) 1-메틸크산틴-기반 생체활성 조성물 및 이의 사용 방법
Ortiz et al. Effect of a positive reinforcing stimulus on fear memory reconsolidation in ethanol withdrawn rats: Influence of d-cycloserine
US11484523B1 (en) Compositions for prevention and treatment of symptoms associated with alcohol consumption
MX2022012693A (es) Composicion que comprende metilfolato.
MX2024012638A (es) Composicion que comprende n-acetilcisteina, vitamina d y preferentemente glutation, usos de la misma, y composiciones farmaceuticas y nutraceuticas de los mismos
WO2025008516A3 (en) Indole derivatives with factor b inhibitory activity
US20200237812A1 (en) Compound and Composition for Use in the Preventive and/or Curative Treatment of Diseases of the Central Nervous System Characterised by a Decline in Neuronal Plasticity, in Particular Characterised by a Decline in Synaptic Plasticity
JP2003286164A (ja) アセチルコリンエステラーゼ阻害剤
RU2572720C1 (ru) Комплексное антиникотиновое средство
Sönmez et al. Effects of oral supplementation of mint extract on muscle pain and blood lactate
Xu Magnesium Glycinate
US7645766B1 (en) Method for treatment of depression and depressive mood disorders
US4609656A (en) Medical agent for improving and treating mental symptoms induced by cerebral disturbances
WO2006087420A3 (en) A method for treating heart failure